Navigation Links
Poniard Pharmaceuticals Announces $6.5 Million Financing
Date:12/22/2009

y require the withdrawal of picoplatin from the market; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel and enter into strategic partnerships; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and its Quarterly Report on Form 10-Q for the period ended September 30, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

SOURCE Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart data solutions ... a record-breaking year across the board for the company. ... Platform and our Smart Data solutions, our customers were able ... led to record growth for the company in 2014,” said ...
(Date:1/22/2015)... Rootstown, OH (PRWEB) January 22, 2015 Crystal ... announced today that it has received AOAC-PTM Certifications for the ... O111, O121, and O145; collectively referred to as STEC or ... at 1 colony forming unit (cfu) per 325 g of ...
(Date:1/22/2015)... Madison, WI (PRWEB) January 22, 2015 Dr. ... at the 12th annual Scripps Natural Supplements Pre-Conference seminar on ... Supplements Conference is an annual continuing education conference for health ... 15th and included the topic of probiotics in health. Dr. ...
(Date:1/22/2015)... Diagenode, Inc., a leading global provider ... complete solutions for epigenetics research, recently launched a ... need for manual processing. The new ChIPettor System ... histones or transcription factors and a semi-automated pipette ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... Purpose , ... the new Q TRAP LC/MS/MS system with Metabolite ID software for Phase ... increase your productivity and confidence in your results. , ... Current trends in drug development are placing more emphasis on ...
... Jason S. Wood, Varian, Inc. , ... Cytochrome P450s (CYPs) are heme-containing ... 1 . CYPs are part of the Phase I (oxidative) metabolism ... drug enabling either easy elimination of the drug or further conjugation ...
... , Z. Yang and S. ... Introduction , Amphetamine ... place, and by recreational users. Forensic, clinical, and doping laboratories are ... Urine samples are most common because large sample volumes can be ...
Cached Biology Technology:Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System 2Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System 3Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System 4Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System 5Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method 2Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method 3Rapid Screening of Amphetamine Drugs in Urine by Positive Ion Electrospray LC/MS/MS 2Rapid Screening of Amphetamine Drugs in Urine by Positive Ion Electrospray LC/MS/MS 3
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season may be ... Market Intelligence reports that the long anticipated floodgates for ... intensifying demand for smart phones, tablets, and wearable mobile ... of 2.5 billion users with nearly 4.8 billion biometric ...
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... a major role in a NASA mission, which they believe ... surface of a comet. , NASA's Deep Impact spacecraft will ... when a metre-long projectile will crash into the comet and ... plume of gas and dust. , UK astronomers involved in ...
... Society of Conservation Biology annual meetings, in Brasília, Brazil, ... Pesquisa Ambiental da Amazonia (IPAM) will hold an international ... resources in the Amazon Basin. , This region has ... the principle industries driving deforestation (cattle ranching and soybean ...
... at U.S. ports, a public enemy has infiltrated the nation's ... a Cornell University expert, the adult female alien is the ... United States. , The discovery of a single specimen of ... across the nation because the invasive insect species has devastated ...
Cached Biology News:NASA probe could reveal comet life, scientists claim 2Alien woodwasp, threat to US pine trees, found in N.Y. 2
Quartz-Halogen, 100 W, High Intensity...
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
Porcine parvovirus and mycoplasma tested. Contains 0.5 g/L of trypsin (1:250) and 0.2 g/L of EDTA4Na in Hanks' Balanced Salt Solution without CaCl2 MgCl2 6H2O and MgSO4 7H2O. Contains phenol red....
... pPIC3.5K vectors carry the kanamycin resistance gene ... Pichia. Spontaneous generation of multiple insertion events ... levels of Geneticin Reagent. Pichia transformants are ... their level of resistance to Geneticin Reagent. ...
Biology Products: